Shahryar Mafi, MD
Cardiovascular Disease · Manassas, VANPI 1750338505
Payments from drug & device makers
Across 448 payments — averaging $31.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Johnson & Johnson$1K
- Novo Nordisk$1K
- Abbott$1K
- Cvrx, Inc.$886
- Amgen$665
- plus $7K from 34 others
What the payments were for
- Food & beverage$14,229100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 94 | $2,137 |
| Johnson & Johnson | 55 | $1,138 |
| Novo Nordisk | 23 | $1,112 |
| Abbott | 11 | $1,019 |
| Cvrx, Inc. | 11 | $886 |
| Amgen | 27 | $665 |
| Pfizer | 26 | $647 |
| Merck | 31 | $645 |
| Scpharmaceuticals Inc. | 23 | $626 |
| Esperion Therapeutics, Inc. | 24 | $608 |
| E.r. Squibb & Sons, L.L.C. | 20 | $560 |
| Boston Scientific | 6 | $490 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 17 | $456 |
| AstraZeneca | 11 | $399 |
| Edwards Lifesciences | 2 | $391 |
| Medtronic(2 entities) | 3 | $292 |
| Heartflow, Inc. | 4 | $248 |
| Amarin Pharma, Inc. | 6 | $233 |
| Boehringer Ingelheim | 6 | $226 |
| Bridgebio Pharma, Inc. | 2 | $171 |
| Bayer | 4 | $164 |
| Kestra Medical Technology Services, Inc. | 4 | $161 |
| Regeneron Healthcare Solutions, Inc. | 8 | $154 |
| Atricure, Inc. | 1 | $134 |
| Sanofi-aventis U.S. LLC | 7 | $127 |
| Cardiovascular Systems Inc. | 2 | $121 |
| Kowa Pharmaceuticals America, Inc. | 3 | $56 |
| Philips North America LLC | 1 | $50 |
| Baxter Healthcare | 1 | $49 |
| Gilead | 3 | $45 |
| Chiesi USA, Inc. | 2 | $41 |
| Amryt Pharma Holdings Ltd | 2 | $31 |
| Recor Medical Inc | 1 | $28 |
| Abiomed | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Qorumpartners | 1 | $21 |
| Coala Life Inc | 1 | $18 |
| Medicomp Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$774
- ENTRESTO$467
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$391
- LEQVIO$363
- Ozempic$334
- JOT DX$268
- Repatha$249
- VERQUVO$245
- FUROSCIX$244
- XARELTO$234
- NEXLETOL$233
- FFRct$226
- GENERAL TACHY$189
- Mitra Clip system$150
- CardioMEMS HF System$147
- Attruby$144
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$134
- CAMZYOS$126
- AVEIR$126
- Vascepa$125
How this compares
$14,255 in reported general payments places this provider in the 80th percentile of 548 cardiovascular disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 387 | $460,015 |
| EntrestoSacubitril/Valsartan | 249 | $365,141 |
| XareltoRivaroxaban | 99 | $131,022 |
| FarxigaDapagliflozin Propanediol | 82 | $91,520 |
| OzempicSemaglutide | 67 | $88,237 |
| JardianceEmpagliflozin | 66 | $74,521 |
| Repatha SureclickEvolocumab | 60 | $62,311 |
| BrilintaTicagrelor | 33 | $41,727 |
| NexlizetBempedoic Acid/Ezetimibe | 18 | $18,000 |
| VerquvoVericiguat | 22 | $17,741 |
| Ranolazine ErRanolazine | 98 | $13,981 |
| Rosuvastatin Calcium | 662 | $9,240 |
| VascepaIcosapent Ethyl | 21 | $7,353 |
| Valsartan | 198 | $6,376 |
| Nebivolol Hcl | 100 | $5,640 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $647 | $460,015387 claims |
| NovartisEntresto | $2,137 | $365,141249 claims |
| AstraZenecaFarxiga, Brilinta | $399 | $133,246115 claims |
| Johnson & JohnsonXarelto | $1,138 | $131,02299 claims |
| Novo NordiskOzempic | $1,112 | $88,23767 claims |
| Boehringer IngelheimJardiance | $226 | $74,52166 claims |
| Esperion Therapeutics, Inc.Nexlizet | $608 | $18,00018 claims |
| MerckVerquvo | $645 | $17,74122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 548 cardiovascular disease providers in Virginia.
Other cardiovascular disease in Manassas
- Hamid TaheriManassas$4.9M
- Vikram PrasannaManassas$880K
- Shahram YazdaniManassas$638K
- Keith ChuManassas$464K
- Khalid AbousyManassas$68K
- Tariq HaddadFalls Church$8M
- David LimCharlottesville$6M
- Philip OdonnellWinchester$4.6M
- Antonio AbbateCharlottesville$4M
- George VetrovecRichmond$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.